U.S., March 20 -- ClinicalTrials.gov registry received information related to the study (NCT06883526) titled 'Study of ZG005 in Combination With Gecacitinib in Patients With Relapsed or Refractory Lymphoma' on March 13.
Brief Summary: PART 1:
1. To explore the safety of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
2. To determine the recommended Phase II dosing regimen for relapsed or refractory lymphoma.
PART 2:
To evaluate the efficacy of ZG005 in combination with Gecacitinib in patients with relapsed or refractory lymphoma.
Study Start Date: May, 2025
Study Type: INTERVENTIONAL
Condition:
Lymphoma
Intervention:
BIOLOGICAL: ZG005 for Injection
intravenous infusion
DRUG: Gecacitinib H...